Biogen Phase Ib Data Positions Salanersen for SMA Treatment Sequencing

Why It Matters

The data suggest salanersen could complement existing gene‑therapy options, offering a durable, once‑yearly regimen that may improve long‑term outcomes and simplify SMA treatment sequencing.

Key Takeaways

• Phase Ib shows 75% neurofilament light reduction.
• Half of participants reached new WHO motor milestones.
• Once‑yearly dosing to be tested in global Phase III.
• STELLAR studies will compare gene therapy, salanersen, combos.
• Therapy generally well tolerated; mild respiratory and fever events.

Pulse Analysis

Spinal muscular atrophy has become a showcase for rapid therapeutic innovation, moving from supportive care to gene‑replacement and small‑molecule approaches within a decade. Yet many patients who receive onasemnogene abeparvovec still face residual weakness or disease progression, creating a demand for adjunctive therapies that can sustain motor function over a lifetime. Salanersen, an antisense oligonucleotide designed to modulate SMN2 splicing, enters this space with a chemistry that supports high potency and the prospect of once‑yearly administration, potentially reducing treatment burden compared with more frequent dosing schedules.

The Phase Ib trial, presented at the Muscular Dystrophy Association conference, enrolled 24 children aged six months to 12 years who remained symptomatic after gene therapy. Biomarker analysis revealed an average 75% decline in neurofilament light chain—a marker of neuronal injury—within six months, and these reductions persisted throughout the follow‑up year. Clinically, every participant showed improvement on at least one endpoint, and 12 achieved a new motor milestone as defined by the World Health Organization. Safety signals were modest, limited to mild respiratory infections and occasional fever, reinforcing the therapy’s tolerability profile.

Biogen’s next step is a three‑arm Phase III program—STELLAR‑1, STELLAR‑2, and SOLAR—targeting distinct SMA cohorts, from presymptomatic newborns to adolescents and adults. By juxtaposing salanersen alone, gene therapy alone, and combination regimens, the studies aim to define optimal sequencing strategies that could become a new standard of care. Successful outcomes would not only broaden therapeutic options for clinicians but also create a market niche for a once‑yearly, disease‑modifying product, potentially reshaping pricing dynamics and payer considerations in the neuromuscular space.